CONFERENCE ROUNDUP

Phase 3 data evaluating eye implant with ranibizumab for wet AMD to be presented at ASRS

Phase 3 clinical trial from the ARCHWAY study evaluating Roche’s Port Delivery System (PDS) with ranibizumab in patients with neovascular age-related macular degeneration (wet AMD), will be presented Sunday, July 26, at the American Society of Retina Specialists Annual Meeting. The eye implant, which continuously delivers a customized formulation of...